Cardiac Marker Testing Market - By Product, By Biomarker Type, By Application, By Distribution Channel, By End-use & Forecast, 2023

Description

List of Tables

Global Cardiac Marker Testing Market will gain significant momentum over 2023-2032, owing to the rising prevalence of cardiovascular diseases (CVDs) worldwide, propelling the demand for effective diagnostic tools.

Cardiac markers serve as crucial indicators of heart conditions and aid in the early detection and management of CVDs. Advancements in technology have led to the development of more sensitive and accurate cardiac marker tests, enhancing their diagnostic capabilities. Additionally, the increasing adoption of point-of-care testing and the need for rapid and efficient diagnosis further contribute to market growth. Moreover, the aging population, changing lifestyles, and the emphasis on preventive healthcare drive the adoption of cardiac marker testing.

The overall cardiac marker testing market is segregated based on product, biomarker, application, distribution channel, end-use, and region.

Regarding the product, analyzers will witness high demand during 2023-2032. The increasing demand for accurate and efficient diagnostic tools driven by the prevalence of cardiovascular diseases will drive segment gains. Advancements in cardiac analyzer technology have improved their capabilities in detecting and monitoring cardiac biomarkers, contributing to their increased adoption. Additionally, the need for faster and more reliable results, along with the emphasis on preventive healthcare, further drives the demand for cardiac analyzers in the medical field.

With regard to biomarkers, the cardiac market testing market share from the creatine kinase segment will depict commendable growth through 2032. Creatine Kinase is an important enzyme that plays a vital role in energy metabolism, making it a key indicator of heart muscle damage. CK biomarkers provide valuable insights into cardiac health and help diagnose and monitor cardiovascular diseases. Additionally, advancements in testing techniques and the increasing adoption of CK biomarkers in clinical settings contribute to their growing demand in cardiac marker testing.

Based on application, the cardiac marker testing market value from the acute coronary syndrome segment will grow significantly from 2023 to 2032. Accurate and timely diagnosis of ACS is crucial for appropriate management and intervention. Cardiac markers, such as troponin, play a vital role in detecting myocardial injury and aiding in ACS diagnosis. The rising prevalence of ACS cases globally and the increasing emphasis on early detection and treatment contribute to the growing adoption of cardiac marker testing in ACS. Additionally, advancements in cardiac marker testing technologies have improved sensitivity and specificity, further driving their demand in ACS diagnosis.

Europe cardiac marker testing industry will capture a recognizable market share by 2032. The high burden of cardiovascular diseases (CVDs) in Europe will favor regional market growth. Increasing aging population and changing lifestyles contribute to the rising incidence of CVDs, leading to increased popularity of cardiac marker testing. Additionally, the implementation of healthcare policies emphasizing early detection and management of CVDs further fuels market growth in Europe.

Product Code: 5614

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Cardiac marker testing industry 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Regional trends
2.4 Product trends
2.5 Biomarker type trends
2.6 Application trends
2.7 Distribution channel trends
2.8 End-use trends

Chapter 3 Cardiac Marker Testing Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of cardiovascular diseases
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Increasing funding from public and private organizations for R&D
  - 3.2.1.4 Rising demand for point-of-care (POC) testing
  - 3.2.1.5 Increasing government initiatives for the diagnosis of cardiac diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory frameworks
  - 3.2.2.2 Lack of skilled professionals
  - 3.2.2.3 Availability of substitute product
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By biomarker type
- 3.3.3 By application
- 3.3.4 By distribution channel
- 3.3.5 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022
3.6 Regulatory landscape
- 3.6.1 U.S.
- 3.6.2 Europe
3.7 Technology landscape
3.8 Future market trends
3.9 Gap analysis
3.10 Porter's analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis
4.6 Strategy dashboard

Chapter 5 Cardiac Marker Testing Market Size and Forecast, By Product (USD Million & Units)

5.1 Key trends, by product
5.2 Consumables
5.3 Analyzers

Chapter 6 Cardiac Marker Testing Market Size and Forecast, By Biomarker Type (USD Million)

6.1 Key trends, by biomarker type
6.2 Troponins
6.3 Myoglobin
6.4 Creatine kinase (CK-MB)
6.5 Brain natriuretic peptide (BNP)
6.6 Ischemia modified albumin (IMA)
6.7 Others

Chapter 7 Cardiac Marker Testing Market Size and Forecast, By Application (USD Million)

7.1 Key trends, by application
7.2 Myocardial infarction
7.3 Congestive heart failure
7.4 Acute coronary syndrome
7.5 Atherosclerosis
7.6 Others

Chapter 8 Cardiac Marker Testing Market Size and Forecast, By Distribution Channel (USD Million)

8.1 Key trends, by distribution channel
8.2 Hospital pharmacies
8.3 Brick & mortar
8.4 E-commerce

Chapter 9 Cardiac Marker Testing Market Size and Forecast, By End-use (USD Million)

9.1 Key trends, by end-use
9.2 Hospitals
9.3 Diagnostic centers
9.4 Others

Chapter 10 Cardiac Marker Testing Market Size and Forecast, By Region (USD Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Poland
- 10.3.7 Sweden
- 10.3.8 The Netherlands
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Thailand
- 10.4.7 Indonesia
- 10.4.8 Philippines
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Columbia
- 10.5.5 Chile
- 10.5.6 Peru
10.6 MEA
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Israel
- 10.6.5 Turkey
- 10.6.6 Iran

Chapter 11 Company Profiles

11.1 Abbott
11.2 Becton, Dickinson and Company
11.3 Biomerieux SA
11.4 Bio-Rad Laboratories, Inc.
11.5 Creative Diagnostics
11.6 Danaher Corporation
11.7 F. Hoffmann-La Roche Ltd.
11.8 Life Diagnostics
11.9 Perkin Elmer Inc.
11.10 Quidel Corporation
11.11 Randox Laboratories Ltd.
11.12 Siemens Healthineers
11.13 Thermo Fisher Scientific